Literature DB >> 19917541

Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.

Joaquim Bosch-Barrera1, Jaime Espinós, Asier Gómez-Ibáñez, Jaime Gállego Pérez-Larraya, Jorge Iriarte.   

Abstract

Ixabepilone is a novel microtubule-stabilising agent used as monotherapy or in combination with capecitabine to treat taxane- and anthracycline-refractory breast cancer. We report the case of a patient who experienced an unusual motor neuropathy after the first cycle. This is a very uncommon secondary effect, but it must be taken into account as a possible complication of treatment with ixabepilone.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19917541     DOI： 10.1007/s12094-009-0440-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  9 in total

Review 1.  Peripheral neuropathy induced by microtubule-stabilizing agents.

Authors:  James J Lee; Sandra M Swain
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

2.  A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Authors:  Owen A O'Connor; Carol Portlock; Craig Moskowitz; David Straus; Paul Hamlin; Michael Stubblefield; Otila Dumetrescu; A Dimitrios Colevas; Barbara Grant; Andrew Zelenetz
Journal:  Br J Haematol       Date:  2008-08-04       Impact factor: 6.998

Review 3.  Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.

Authors:  Meghana Trivedi; Imawati Budihardjo; Kirsten Loureiro; Tony R Reid; Joseph D Ma
Journal:  Future Oncol       Date:  2008-08       Impact factor: 3.404

Review 4.  Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Authors:  Michael Steinberg
Journal:  Clin Ther       Date:  2008-09       Impact factor: 3.393

Review 5.  Application of epothilones in breast cancer therapy.

Authors:  Mary Cianfrocca
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

Review 6.  Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.

Authors:  Shriya Bhushan; Christine M Walko
Journal:  Ann Pharmacother       Date:  2008-07-22       Impact factor: 3.154

7.  Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.

Authors:  S Goel; G L Goldberg; D Y-S Kuo; F Muggia; J Arezzo; S Mani
Journal:  Ann Oncol       Date:  2008-07-21       Impact factor: 32.976

8.  Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

Authors:  Edith A Perez; Guillermo Lerzo; Xavier Pivot; Eva Thomas; Linda Vahdat; Linda Bosserman; Patrice Viens; Can Cai; Brian Mullaney; Ronald Peck; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544

Review 9.  Peripheral nerve damage associated with administration of taxanes in patients with cancer.

Authors:  Andreas A Argyriou; Martin Koltzenburg; Panagiotis Polychronopoulos; Spiridon Papapetropoulos; Haralabos P Kalofonos
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-07       Impact factor: 6.312
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.